{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T12:42:23Z","timestamp":1747226543214,"version":"3.40.5"},"reference-count":0,"publisher":"Weston Medical Publishing","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Opioid Management"],"abstract":"<jats:p>Buprenorphine-naloxone is a combination medication of an opioid partial agonist and opioid antagonist that is proven to be effective in outpatient management of opioid use disorder (OUD). Tramadol is a centrally acting analgesic. This commonly used pain medication inhibits serotonin and noradrenaline reuptake by acting as a selective agonist on opioid \u03bc receptors. Transition and tapering high-dose tramadol to buprenorphine-naloxone is not well described in the literature. We report a case of a patient who was taking 1,000-1,250 mg of tramadol daily upon presentation to the clinic. She was originally prescribed 150 mg daily with escalation in dose and frequency over a 10-year period. The patient was converted to buprenorphine-naloxone and has been successful in treatment of OUD for 1 year.\u00a0<\/jats:p>","DOI":"10.5055\/jom.2023.0774","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:37:09Z","timestamp":1678495029000},"page":"187-190","source":"Crossref","is-referenced-by-count":1,"title":["High-dose tramadol conversion to buprenorphine-naloxone"],"prefix":"10.5055","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5144-7780","authenticated-orcid":false,"given":"Julienne K.","family":"Kirk, PharmD, BCPS","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte T.","family":"Boyd, MA, CHES","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Cassidy-Vu, MD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda P.","family":"McRae, PsyD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather E.","family":"Strickland, NP-C","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest Blake","family":"Fagan, MD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3008","published-online":{"date-parts":[[2023,3,1]]},"container-title":["Journal of Opioid Management"],"original-title":[],"link":[{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/3370\/3661","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/3370\/3661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T18:54:06Z","timestamp":1682967246000},"score":1,"resource":{"primary":{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/view\/3370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.5055\/jom.2023.0774","relation":{},"ISSN":["1551-7489","1551-7489"],"issn-type":[{"type":"electronic","value":"1551-7489"},{"type":"print","value":"1551-7489"}],"subject":[],"published":{"date-parts":[[2023,3,1]]}}}